Le Lézard
Classified in: Business
Subject: STR

IIROC Trading Resumption - GUS


VANCOUVER, BC, June 27, 2022 /CNW/ - Trading resumes in:

Company: Angus Gold Inc.

TSX-Venture Symbol: GUS

All Issues: Yes

Resumption (ET): 9:30 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


These press releases may also interest you

at 19:53
Earlier today the Senate voted to pass the Inflation Reduction Act of 2022, a bill that includes several key provisions to lower the prices of prescription drugs. AARP Illinois thanks Senators Tammy Duckworth and Senate Majority Whip Dick Durbin for...

at 15:46
Blue Cross Blue Shield Association President and CEO Kim Keck issued the following statement today in response to the passage of the Inflation Reduction Act, which extends Affordable Care Act (ACA) tax credits for three years....

at 11:23
Partner Communications Company Ltd. ("Partner" or the "Company") , a leading Israeli communications operator reports today that Standard & Poor's Global Ratings Maalot Ltd. ("Maalot"), has published a rating report regarding the Company. In its...

at 11:16
Harvest Commodities' ship, M/V Riva Wind, has departed from the Port of Odessa, Ukraine with 50,000 tons of grain, and the second ship, M/V Arizona, has left the Port of Chornomorsk, Ukraine with 55,000 tons of grain. The grain belongs to a joint...

at 03:20
BiomX Inc. ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio...

6 aoû 2022
Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured $20 million in...



News published on 27 june 2022 at 08:17 and distributed by: